ImmunoGen, Inc. To Present at the UBS 2007 Global Life Sciences Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 20, 2007--ImmunoGen, Inc. (Nasdaq: IMGN) is scheduled to present at the UBS 2007 Global Life Sciences Conference at 2:30 pm EDT on September 27, 2007. The presentation will be webcast live and can be accessed through the "Investor Relations" section of the ImmunoGen website, www.immunogen.com. An archive of the webcast will be available at the same location until October 4, 2007.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. ImmunoGen's proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Two TAP compounds wholly owned by ImmunoGen are in clinical testing - huN901-DM1 and huC242-DM4. Three anticancer compounds, two of which are TAP compounds, are in clinical testing through ImmunoGen's collaborations with other companies - AVE9633 and AVE1642, in development by sanofi-aventis, and trastuzumab-DM1 (T-DM1), in development by Genentech. Multiple compounds are in research/preclinical development.
CONTACT:
Investors
ImmunoGen, Inc.
Carol Hausner, 617-995-2500
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com
